HQL
Abrdn Life Sciences Investors16.81
-0.23-1.35%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
497.55MP/E (TTM)
6.03Basic EPS (TTM)
2.79Dividend Yield
0.11%Recent Filings
8-K
Auditor resigns over independence
Tekla Life Sciences Investors' auditor Deloitte & Touche resigned on September 6, 2023, due to an independence issue from a pending transaction between Tekla Capital Management and abrdn Inc., with the board approving the move the next day. No disagreements or reportable events marred Deloitte's clean reports for fiscal years 2021 and 2022. The board swiftly engaged KPMG as the new auditor for the year ending September 30, 2023. This switch ensures compliance amid the affiliation shift.
8-K
Share repurchase renewal announced
H&Q Life Sciences Investors renewed its share repurchase program on March 22, 2013, authorizing open-market buys of up to 12% of outstanding common shares through July 10, 2014. This move aims to boost net asset value per share and narrow the market price discount to NAV, while enhancing trading liquidity. Repurchases hinge on adviser discretion. No guarantees on outcomes.
8-K
Share repurchase renewal announced
H&Q Life Sciences Investors renewed its share repurchase program on March 23, 2012, authorizing open-market buys of up to 12% of outstanding common shares over the year starting July 11, 2012. This move aims to boost net asset value per share and narrow the market price discount to NAV, while enhancing trading liquidity. Repurchases hinge on adviser discretion. No guarantees exist on outcomes.
8-K
Share repurchase program authorized
H&Q Life Sciences Investors' Board authorized a share repurchase program on June 30, 2011, enabling open-market buys of up to 12% of outstanding common shares over one year starting July 11. This move aims to boost net asset value per share and narrow the market price discount to NAV, while enhancing trading liquidity. Repurchases, at the adviser's discretion, carry no guarantees of price gains. The Board will track impacts on expenses and strategy.
8-K
Tender offer for 35% shares
H&Q Life Sciences Investors' shareholders approved an amendment to the Declaration of Trust on May 2, 2011, lifting restrictions on trustees' share repurchase powers. The fund launched a cash tender offer on May 3 to buy up to 35% of outstanding shares at 98% of NAV as of June 1, 2011. This move, backed by the investment adviser, stems from a compromise with activist Western Investment, curbing their proposals for five years. Liquidity boosts for shareholders, yet at a discount.
AEF
27762
6.78-0.11
AGD
"abrdn Global Dynamic Dividend
11.43+0.00
AOD
Aberdeen Total Dynamic Dividend
9.64-0.07
AWP
Aberdeen Global Premier Propert
3.89+0.00
BME
Blackrock Health Sciences Trust
40.60-0.47
HQH
Tekla Healthcare Investors
18.80-0.20
IAF
61617
13.06+0.27
JEQ
Aberdeen Japan Equity Fund, Inc
8.05-0.24
THQ
Tekla Healthcare Opportunies Fu
18.67-0.26
THW
Tekla World Healthcare Fund Sha
12.42-0.21